Renal Anemia | Access and Reimbursement | US | 2020
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and medical directors. We explore how payers and physicians interact and how reimbursement decisions affect the prescribing and uptake of specific therapies at the brand level.
QUESTIONS ANSWERED
- How do payers reimburse specific therapies for the treatment of renal anemia, and what restrictions do they impose?
- What factors most influence payers’ reimbursement decisions for specific renal anemia therapies?
- What roles do reimbursement, restrictions, and patient costs play in physicians’ choice of therapy for this indication?
- How do payers anticipate reimbursing emerging therapies at various prices?
- What patient share can emerging therapies garner under various reimbursement scenarios?
- How can pharmaceutical companies enable their products to thrive in this market access environment?
Related Market Assessment Reports
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
